Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.65), $0.11 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $192.8 million versus the consensus estimate of $174.51 million.

GUIDANCE:

Tandem Diabetes sees Q2 2024 revenue of $205 million, versus the consensus of $205 million.

Tandem Diabetes sees FY2024 revenue of $868 million, versus the consensus of $845.5 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.